NI company unveils world’s first clinical trial on omega-3

Devenish RCSI Alice Stanton
Devenish RCSI Alice Stanton

A world-first clinical trial delivered by the Royal College of Surgeons in Ireland, on behalf of Belfast-headquartered farming and food company Devenish, has proven that the regular consumption of naturally enriched omega-3 chicken and eggs is likely to reduce risk of heart attack, stroke, dementia and depression.

The results of the novel six-month clinical trial were presented on a world stage at the American Heart Association Scientific Sessions Conference in Anaheim, California, on 14th November 2017.

The 161 subjects involved in the study consumed at least three portions of chicken and eggs per week, that were naturally enriched with omega-3 Polyunsaturated Fatty Acids (PUFA), the same nutrients found in oily fish.

The results from the clinical study saw an increase in omega-3-PUFA levels in blood and a positive shift in what is described as the ‘omega-3 Index’-a test that measures the amount of the omega-3 fatty acids, Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in red blood cell membranes, which reflects the levels in your heart and other tissues. A low omega-3 Index (<4%) indicates a heightened risk of heart and brain disease. The study showed that consuming omega-3 enriched chicken and eggs resulted in a halving of the number of subjects with such a high-risk omega-3 Index. The chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish. The findings were presented by Professor Alice Stanton of The Royal College of Surgeons in Ireland.